BODULUVE
DEAD

Serial Number

98542751

Owner

SAMSUNG BIOEPIS CO., LTD.

Attorney

Charles T. J. Weigell

Filing Date

May 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BODULUVE Trademark

Serial Number: 98542751

BODULUVE is a trademark filed by SAMSUNG BIOEPIS CO., LTD. on May 9, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

SAMSUNG BIOEPIS CO., LTD. (58 trademarks)

76, Songdogyoyuk-ro, Yeonsu-gu

Entity Type: 03

Trademark Details

Filing Date

May 9, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of hematological, autoimmune, inflammatory, respiratory, and transplantation-related diseases and disorders; pharmaceutical preparations for the treatment of generalized myasthenia gravis; dietary supplements; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; human vaccine preparations; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations, namely, pharmaceutical preparations, biological formulations, biological preparations, antibody formulations and protein formulations for immunoregulation and for treatment of immunologic disorders, autoimmune diseases, inflammatory diseases, arthritis, cancer, tumor, central nervous system disorders and metabolic diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; nutraceuticals for medical purposes; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for tumor treatment; preparations for treatment of cancer; preparations for treatment of tumour diseases; preparations for treatment of multiple myeloma; pharmaceutical preparations for the treatment of skeletal diseases; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of solid cancer

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 4, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 4, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 17, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 7, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 9, 2024 NWOS
NEW APPLICATION ENTERED
May 9, 2024 NWAP